广济药业：预计2025年亏损5.18亿元至3.99亿元，产能利用率及整体经营业绩未达预期

Core Viewpoint - Guangji Pharmaceutical (000952) expects a net profit loss of approximately 518 million to 399 million yuan for the fiscal year 2025 due to intensified market competition and prolonged low sales prices of its main products [1] Group 1: Financial Performance - The company is currently experiencing operational losses as capacity utilization and overall business performance have not met expectations [1] - Several subsidiaries under the company have not shown effective improvement in their operational status, continuing to incur losses [1] Group 2: Market Conditions - The company faces multiple adverse factors, including insufficient production line operating rates and declining market prices for its products, which have led to significant impairment signs for related assets [1] - The company has made provisions for asset impairment based on a cautious principle, with the final impairment amount to be determined by professional assessments from hired evaluation agencies and accounting firms [1]